Home
Science & Medicine
Diagnostic Oncology
Evolving Standards of Care
FDA Corner
Global Initiatives
Immunotherapy
Lung Cancer Screening
NCI Corner
Pathology
Prevention and Tobacco Control
Radiation Oncology
Supportive Care
Targeted Therapy
Advocacy & Survivorship
Thought-Leader Perspective
Allied Health
Meetings
Highlights
Preview
News
Breaking News Briefs
In Memoriam
People
Search
IASLC.org
IASLC Lung Cancer News
Home
Science & Medicine
Diagnostic Oncology
Evolving Standards of Care
FDA Corner
Global Initiatives
Immunotherapy
Lung Cancer Screening
NCI Corner
Pathology
Prevention and Tobacco Control
Radiation Oncology
Supportive Care
Targeted Therapy
Advocacy & Survivorship
Thought-Leader Perspective
Allied Health
Meetings
Highlights
Preview
News
Breaking News Briefs
In Memoriam
People
Home
Meetings
Meetings
Most popular
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Best of the 16th WCLC in Athens, Greece
lungcanc
WCLC 2016 Together Against Lung Cancer
7th IASLC Latin American Conference on Lung Cancer
The Long Road Home
The IASLC’s Spotlight on Screening
4th AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the...
lungcanc
TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse
lungcanc
IASLC and APLCC Present 7th IASLC Asia Pacific Lung Cancer Conference
lungcanc
IASLC World Conference on Lung Cancer 2016 Together Against Lung Cancer
lungcanc
Scientific Highlights from the IASLC Latin America Conference on Lung Cancer
lungcanc
IASLC 2020 World Conference on Lung Cancer Postponed
lungcanc
5th AACR-IASLC International Joint Conference: Translational Progress through Basic Research
lungcanc
cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib
lungcanc
Best of the 16th World Conference on Lung Cancer in Peru
lungcanc
Best of IASLC WCLC 2016
lungcanc
1
2
3
...
6
Page 1 of 6
Meeting News
Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation
Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation
TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse
cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib
Load more
Edit with Live CSS
